The purpose of this legislation, known as the Alzheimer's Early Detection Act of 2026, is to ensure that Alzheimer's biomarker testing is covered by health insurance plans and the Medicaid program. The goal is to improve early detection and management of Alzheimer's disease, which can lead to better treatment outcomes for patients. Key provisions of the legislation require that group health plans and individual health insurance policies provide coverage for Alzheimer's biomarker testing without imposing stricter financial or treatment limitations compared to other medical services.